Latest Updates on Myopia Pipeline Analysis in 2023: Recent FDA, EMA, and PMDA Approvals Explored by Pfizer, ALCON Inc., Bausch Health Companies Inc., Essilor Luxottica, and Johnson & Johnson

 Breaking News
  • No posts were found

Latest Updates on Myopia Pipeline Analysis in 2023: Recent FDA, EMA, and PMDA Approvals Explored by Pfizer, ALCON Inc., Bausch Health Companies Inc., Essilor Luxottica, and Johnson & Johnson

December 05
20:57 2023
Latest Updates on Myopia Pipeline Analysis in 2023: Recent FDA, EMA, and PMDA Approvals Explored by Pfizer, ALCON Inc., Bausch Health Companies Inc., Essilor Luxottica, and Johnson & Johnson
Myopia Pipeline

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Myopia pipeline constitutes 10+ key companies continuously working towards developing 12+ Myopia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Myopia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

 

Myopia Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Myopia Market.

 

Some of the key takeaways from the Myopia Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Myopia treatment therapies with a considerable amount of success over the years. 
  • Myopia companies working in the treatment market are Santen Pharmaceutical, Sunhawk Vision Biotech, Nevakar, Inc., Cloudbreak Therapeutics, LLC, iVeena Delivery Systems, Sydnexis, Inc., Nevakar, Inc., and others, are developing therapies for the Myopia treatment 
  • Emerging Myopia therapies in the different phases of clinical trials are- STN-1013400, SHJ002, EXP039, CBT-009, IVMED 85, DE 127, SYD-101, NVK-002, and others are expected to have a significant impact on the Myopia market in the coming years.   
  • In October 2023, The PROTECT clinical trial for Visioneering Technologies Inc.’s (VTI) NaturalVue Multifocal 1 Day paediatric myopia progression control contact lenses produced positive interim one-year findings. The findings, which were presented at the American Academy of Optometry Annual Meeting in October 2023, validate the NaturalVue Multifocal 1 Day contact lenses’ effectiveness and safety in slowing the advancement of myopia.
  • In October 2021, The Food and Drug Administration approved Allergan, an AbbVie subsidiary, to market Vuity (pilocarpine hydrochloric acid ophthalmic solution) 1.25% to treat presbyopia, or age-related hazy near vision, in adults.
  • In May 2021, The US FDA approved Johnson & Johnson Vision’s ACUVUE Abiliti Overnight Therapeutic Lenses, which are intended to help correct children’s progressive myopia by reshaping the cornea.

 

Myopia Overview

The most prevalent type of Refractive Error (RE), known as myopia or shortsightedness, causes a person to have clear near vision but poor distance vision. In this case, near refers to the reading distance of 35–40 cm, and far denotes more than three feet. “Rays of light coming from infinity cannot focus in the retina, instead it is focused in front of the retina, when accommodation function is at rest,” is the clinical definition of myopia.

 

Get a Free Sample PDF Report to know more about Myopia Pipeline Therapeutic Assessment-  https://www.delveinsight.com/report-store/myopia-pipeline-insight

 

Emerging Myopia Drugs Under Different Phases of Clinical Development Include:

  • STN-1013400: Santen Pharmaceutical
  • SHJ002: Sunhawk Vision Biotech
  • EXP039: Nevakar, Inc.
  • CBT-009: Cloudbreak Therapeutics, LLC
  • IVMED 85: iVeena Delivery Systems
  • DE 127: Santen Pharmaceutical
  • SYD-101: Sydnexis, Inc.
  • NVK-002: Nevakar, Inc.

 

Myopia Route of Administration

Myopia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

Myopia Molecule Type

Myopia Products have been categorized under various Molecule types, such as

  • Oligonucleotide
  • Peptide
  • Small molecule

 

Myopia Pipeline Therapeutics Assessment

  • Myopia Assessment by Product Type
  • Myopia By Stage and Product Type
  • Myopia Assessment by Route of Administration
  • Myopia By Stage and Route of Administration
  • Myopia Assessment by Molecule Type
  • Myopia by Stage and Molecule Type

 

DelveInsight’s Myopia Report covers around 12+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Myopia product details are provided in the report. Download the Myopia pipeline report to learn more about the emerging Myopia therapies

 

Some of the key companies in the Myopia Therapeutics Market include:

Key companies developing therapies for Myopia are – ALCON Inc., Bausch Health Companies Inc., Essilor Luxottica (Essilor Ltd), Johnson & Johnson Vision, NIDEK CO. LTD, Topcon Corporation, Zeimer Ophthalmic Systems AG, Carl Zeiss Meditec AG, AbbVie, Sydnexis, Regeneron Pharmaceuticals Inc., Orasis Pharmaceuticals, The Cooper Companies Inc., and others.

 

Myopia Pipeline Analysis:

The Myopia pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Myopia with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myopia Treatment.
  • Myopia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Myopia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myopia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Myopia drugs and therapies

 

Myopia Pipeline Market Drivers

  • Increase in the prevalence of Myopia, increasing Research and Development activities are some of the important factors that are fueling the Myopia Market.

 

Myopia Pipeline Market Barriers

  • However, cost associated with the treatment, unclear pathogenesis of the disease and other factors are creating obstacles in the Myopia Market growth.

 

Scope of Myopia Pipeline Drug Insight    

  • Coverage: Global
  • Key Myopia Companies: Santen Pharmaceutical, Sunhawk Vision Biotech, Nevakar, Inc., Cloudbreak Therapeutics, LLC, iVeena Delivery Systems, Santen Pharmaceutical, Sydnexis, Inc., Nevakar, Inc., and others
  • Key Myopia Therapies: STN-1013400, SHJ002, EXP039, CBT-009, IVMED 85, DE 127, SYD-101, NVK-002, and others
  • Myopia Therapeutic Assessment: Myopia current marketed and Myopia emerging therapies
  • Myopia Market Dynamics: Myopia market drivers and Myopia market barriers 

 

Request for Sample PDF Report for Myopia Pipeline Assessment and clinical trials

 

Table of Contents

1. Myopia Report Introduction

2. Myopia Executive Summary

3. Myopia Overview

4. Myopia- Analytical Perspective In-depth Commercial Assessment

5. Myopia Pipeline Therapeutics

6. Myopia Late Stage Products (Phase II/III)

7. Myopia Mid Stage Products (Phase II)

8. Myopia Early Stage Products (Phase I)

9. Myopia Preclinical Stage Products

10. Myopia Therapeutics Assessment

11. Myopia Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Myopia Key Companies

14. Myopia Key Products

15. Myopia Unmet Needs

16 . Myopia Market Drivers and Barriers

17. Myopia Future Perspectives and Conclusion

18. Myopia Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services

Related Articles

Categories